Cargando…

Plasma Catestatin: A Useful Biomarker for Coronary Collateral Development with Chronic Myocardial Ischemia

BACKGROUNDS: Catestatin is an endogenous multifunctional neuroendocrinepeptide. Recently, catestatin was discovered as a novel angiogenic cytokine. The study was to investigate the associations between endogenous catestatin and coronary collateral development among the patients with chronic myocardi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Weixian, Yu, Haiyi, Li, Weihong, Gao, Wei, Guo, Lijun, Wang, Guisong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909297/
https://www.ncbi.nlm.nih.gov/pubmed/27304618
http://dx.doi.org/10.1371/journal.pone.0149062
_version_ 1782437815806590976
author Xu, Weixian
Yu, Haiyi
Li, Weihong
Gao, Wei
Guo, Lijun
Wang, Guisong
author_facet Xu, Weixian
Yu, Haiyi
Li, Weihong
Gao, Wei
Guo, Lijun
Wang, Guisong
author_sort Xu, Weixian
collection PubMed
description BACKGROUNDS: Catestatin is an endogenous multifunctional neuroendocrinepeptide. Recently, catestatin was discovered as a novel angiogenic cytokine. The study was to investigate the associations between endogenous catestatin and coronary collateral development among the patients with chronic myocardial ischemia. METHODS: Thirty-eight patients with coronary artery chronic total occlusions (CTO) (CTO group) and 38 patients with normal coronary arteries (normal group) were enrolled in the series. Among the patients with CTO, coronary collateral development was graded according to the Rentrop score method. Rentrop score 0–1 collateral development was regarded as poor collateral group and 2–3 collateral development was regarded as good collateral group. Plasma catestatin level and vascular endothelial growth factor (VEGF) were measured by ELISA kits. RESULTS: The plasma catestatin levels in CTO group were significantly higher than that in normal group (1.97±1.01 vs 1.36±0.97ng/ml, p = 0.009). In the CTO group, the patients with good collateral development had significantly higher catestatin and VEGF levels than those with poor collateral development (2.36±0.73 vs 1.61±1.12 ng/ml, p = 0.018; 425.23±140.10 vs 238.48±101.00pg/mL, p<0.001). There is a positive correlation between plasma catestatin levels and Rentrop scores (r = 0.40, p = 0.013) among the patients with CTO. However, there is no correlations between plasma catestatin levels and VEGF (r = -0.06, p = 0.744). In the multiple linear regression models, plasma catestatin level was one of the independent factors of coronary collateral development after adjustment for confounders. CONCLUSIONS: Plasma catestatin was associated with coronary collateral developments. It may be a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis in patients with CTO.
format Online
Article
Text
id pubmed-4909297
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-49092972016-07-06 Plasma Catestatin: A Useful Biomarker for Coronary Collateral Development with Chronic Myocardial Ischemia Xu, Weixian Yu, Haiyi Li, Weihong Gao, Wei Guo, Lijun Wang, Guisong PLoS One Research Article BACKGROUNDS: Catestatin is an endogenous multifunctional neuroendocrinepeptide. Recently, catestatin was discovered as a novel angiogenic cytokine. The study was to investigate the associations between endogenous catestatin and coronary collateral development among the patients with chronic myocardial ischemia. METHODS: Thirty-eight patients with coronary artery chronic total occlusions (CTO) (CTO group) and 38 patients with normal coronary arteries (normal group) were enrolled in the series. Among the patients with CTO, coronary collateral development was graded according to the Rentrop score method. Rentrop score 0–1 collateral development was regarded as poor collateral group and 2–3 collateral development was regarded as good collateral group. Plasma catestatin level and vascular endothelial growth factor (VEGF) were measured by ELISA kits. RESULTS: The plasma catestatin levels in CTO group were significantly higher than that in normal group (1.97±1.01 vs 1.36±0.97ng/ml, p = 0.009). In the CTO group, the patients with good collateral development had significantly higher catestatin and VEGF levels than those with poor collateral development (2.36±0.73 vs 1.61±1.12 ng/ml, p = 0.018; 425.23±140.10 vs 238.48±101.00pg/mL, p<0.001). There is a positive correlation between plasma catestatin levels and Rentrop scores (r = 0.40, p = 0.013) among the patients with CTO. However, there is no correlations between plasma catestatin levels and VEGF (r = -0.06, p = 0.744). In the multiple linear regression models, plasma catestatin level was one of the independent factors of coronary collateral development after adjustment for confounders. CONCLUSIONS: Plasma catestatin was associated with coronary collateral developments. It may be a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis in patients with CTO. Public Library of Science 2016-06-15 /pmc/articles/PMC4909297/ /pubmed/27304618 http://dx.doi.org/10.1371/journal.pone.0149062 Text en © 2016 Xu et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Xu, Weixian
Yu, Haiyi
Li, Weihong
Gao, Wei
Guo, Lijun
Wang, Guisong
Plasma Catestatin: A Useful Biomarker for Coronary Collateral Development with Chronic Myocardial Ischemia
title Plasma Catestatin: A Useful Biomarker for Coronary Collateral Development with Chronic Myocardial Ischemia
title_full Plasma Catestatin: A Useful Biomarker for Coronary Collateral Development with Chronic Myocardial Ischemia
title_fullStr Plasma Catestatin: A Useful Biomarker for Coronary Collateral Development with Chronic Myocardial Ischemia
title_full_unstemmed Plasma Catestatin: A Useful Biomarker for Coronary Collateral Development with Chronic Myocardial Ischemia
title_short Plasma Catestatin: A Useful Biomarker for Coronary Collateral Development with Chronic Myocardial Ischemia
title_sort plasma catestatin: a useful biomarker for coronary collateral development with chronic myocardial ischemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909297/
https://www.ncbi.nlm.nih.gov/pubmed/27304618
http://dx.doi.org/10.1371/journal.pone.0149062
work_keys_str_mv AT xuweixian plasmacatestatinausefulbiomarkerforcoronarycollateraldevelopmentwithchronicmyocardialischemia
AT yuhaiyi plasmacatestatinausefulbiomarkerforcoronarycollateraldevelopmentwithchronicmyocardialischemia
AT liweihong plasmacatestatinausefulbiomarkerforcoronarycollateraldevelopmentwithchronicmyocardialischemia
AT gaowei plasmacatestatinausefulbiomarkerforcoronarycollateraldevelopmentwithchronicmyocardialischemia
AT guolijun plasmacatestatinausefulbiomarkerforcoronarycollateraldevelopmentwithchronicmyocardialischemia
AT wangguisong plasmacatestatinausefulbiomarkerforcoronarycollateraldevelopmentwithchronicmyocardialischemia